S32 is a venture capital firm investing at the frontiers of technology. Founded by Bill Maris, the team has vast experience building iconic companies. Our goal is to accelerate the discovery, development, and distribution of revolutionary technologies that improve the human condition. We invest across the entirety of technology. This includes artificial intelligence, enterprise software, cybersecurity, fintech, quantum computing, computational biology, and biotechnology. Follow us on Twitter: https://twitter.com/S32_VC
Location: United States, California, Palo Alto
Employees: 11-50
Founded date: 2017
Investment Type: Venture Capital
Portfolio 92
| Date | Name | Website | Total Raised | Location |
| - | Metaphysic... | metaphysic.ai | - | United Kin... |
| - | ROME Thera... | rometx.com | $50M | United Sta... |
| - | Primer | primer.ai | $219M | - |
| - | Inworld AI | inworld.ai | $577M | United Sta... |
| - | GeneDx | genedx.com | - | United Sta... |
| - | Nusano | nusano.com | $115M | United Sta... |
| - | Lime | li.me | $1.39B | United Sta... |
| - | Coinbase W... | coinbase.com | $555.17M | United Sta... |
| - | Kestrel Th... | kestreltherapeutics.com | $40M | United Sta... |
| - | Wise Syste... | wisesystems.com | $122M | United Sta... |
Show more
Mentions in press and media 22
| Date | Title | Description |
| 03.06.2025 | Infleqtion's Quantum Leap: $100 Million to Revolutionize Technology | In the heart of Boulder, Colorado, a quantum revolution is brewing. Infleqtion, a company born from the academic halls of the University of Colorado, has just secured a staggering $100 million in Series C funding. This infusion of capital i... |
| 02.06.2025 | Infleqtion closes $100M Series C round | Infleqtion, a quantum technology company that uses lasers to maintain those systems, has fetched roughly $100 million in Series C capital from investors to aid in the further development and scaling of its product offerings. Founded as cold... |
| 12.05.2025 | Inductive Bio: Pioneering the Future of Drug Discovery with $25 Million Series A Funding | In the bustling heart of New York City, a quiet revolution is brewing. Inductive Bio, a trailblazer in artificial intelligence (AI) for small molecule drug discovery, has secured $25 million in Series A funding. This financial boost, led by... |
| 11.05.2025 | Inductive Bio: $25 Million Series A Closed To Transform Small Molecule Drug Discovery | Inductive Bio, a company democratizing AI models to transform small molecule drug discovery, announced that it has raised $25 million in Series A funding led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Healt... |
| 07.04.2025 | SandboxAQ Closes Series E Funding Round | SandBoxAQ, a Palo Alto, CA-based enterprise quantitative AI company, raised an undisclosed amount in Series E funding. Latest investors included Ray Dalio, Horizon Kinetics, BNP Paribas, Google, and NVIDIA, bringing the total amount to over... |
| 07.04.2025 | SandboxAQ Closes Series E Round with Expanded Investor Base | New investments to accelerate SandboxAQ’s innovation in quantitative AI and expand its impact across critical industries SandboxAQ, a global leader in enterprise quantitative AI, announced the addition of Ray Dalio, Horizon Kinetics, BNP Pa... |
| 05.04.2025 | SandboxAQ: Over $450 Million (Series E) Raised For Enterprise Quantitative AI | SandboxAQ, a leader in enterprise quantitative AI, announced the addition of Ray Dalio, Horizon Kinetics, BNP Paribas, Google, and NVIDIA to its Series E funding round that raised over $450 million. These investments emphasize the confidenc... |
| 04.04.2025 | SandboxAQ Adds $150M From Google, Nvidia And Others | 0 Shares Email Facebook Twitter LinkedIn Alphabet spinoff SandboxAQ — an AI and quantum computing startup — added another $150 million to its Series E from the likes of Google and Nvidia. The add-on comes less than four months after the com... |
| 31.03.2025 | Character Biosciences: Pioneering Precision Medicine for Eye Diseases | In the realm of healthcare, precision medicine is the compass guiding us toward targeted therapies. Character Biosciences, a New Jersey-based company, is at the forefront of this revolution. Recently, they secured a hefty $93 million in Ser... |
| 28.03.2025 | Character Biosciences: $93 Million (Series B) Secured For Advancing Precision Medicine For Progressive Eye Diseases | Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies ... |
Show more